Granules India’s arm gets USFDA’s nod for Trospium Chloride Extended-Release Capsules

24 Apr 2020 Evaluate
Granules India’s wholly owned foreign subsidiary -- Granules Pharmaceuticals Inc (GPI), has received approval for its Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (US FDA) for Trospium Chloride Extended-Release Capsules, 60 mg. It is bioequivalent to the reference listed drug product (RLD), Sanctura XR Capsules, 60 mg, of Allergan, Inc.

Trospium Chloride Extended-Release Capsules are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

605.90 -2.90 (-0.48%)
09-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1826.10
Dr. Reddys Lab 1371.60
Cipla 1488.15
Lupin 2251.80
Zydus Lifesciences 1009.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.